Skip to Content
Morningstar

McKesson Corp - Stock Quote MCK

Morningstar Rating
Rating as of

Morningstar's McKesson Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Another Strong Quarter for Narrow-Moat McKesson; Opioid Litigation Case Settled in 48 States

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

Overall, we are pleased with McKesson's fiscal fourth-quarter results. We anticipate a raise in our fair value estimate following a more thorough review of the company's results and 2023 guidance. However, our current take is that the company's strong market performance over the past several months (shares have climbed 35% year to date) has placed the stock in overvalued territory. 

Read Full Analysis

McKesson Corp's Company Profile

Business Description

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Contact
6555 State Highway 161
Irving, TX, 75039
T +1 972 446-4800
Sector Healthcare
Industry Medical Distribution
Most Recent Earnings Mar 31, 2022
Fiscal Year End Mar 31, 2023
Stock Type Classic Growth
Employees 75,000

McKesson Corp's Related Articles & News

Sustainability Matters

What Investors Should Know About the $26 Billion Opioid Settlement

We review potential impact on valuation for the four companies involved.
Karen Wallace
Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen
Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.
Karen Andersen
Fund Spy

Few Can Match Vanguard Dividend Growth's Reliability

The Gold-rated fund continues to prove its worth during volatile markets.
Alec Lucas
Our Picks

15 Top-Quality Stocks

These names were recently added to the Morningstar Wide Moat Focus Index.
Susan Dziubinski
Stock Strategist Industry Reports

What Opioid Litigation Means for Healthcare Stocks

It continues to inflict pain on drug manufacturers and distributors.
Soo Romanoff
Our Picks

10 Cheap Wide-Moat Stocks

We review the changes to the Morningstar Wide Moat Focus Index during the latest reconstitution and reveal the least-expensive names.
Susan Dziubinski
Investing Specialists

Morningstar Runs the Numbers

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended April 12.
Morningstar.com
Stock Strategist Industry Reports

Lowering Our Pharma Distributor Moat Ratings and Valuations

All three companies still trade at 4 stars, however.
Soo Romanoff
Our Picks

30 Undervalued Stocks

Here are some of our analysts' best ideas across sectors.
Susan Dziubinski
Quarter-End Insights

Healthcare: Stock-Picking Increasingly Important

Drug manufacturers and healthcare providers offer the most upside.
Damien Conover
Stock Analyst Update

Steady Top-Line Growth for McKesson

The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
Damien Conover
Premium Article

25 Cheap Stocks

These low- and medium-uncertainty stocks are trading at the largest discounts to our fair value estimates.
Susan Dziubinski
Quarter-End Insights

Healthcare: Specter of ACA Repeal Hangs Over Fairly Valued Sector

We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
Damien Conover
Premium Article

Are These Wide-Moat Stocks Subpar?

More than 50 stocks derive their wide moats from just one source. Is that a problem?
Susan Dziubinski
Stock Strategist

Cardinal's a Critical Link in the Pharma Supply Chain

Its core operations will be needed no matter how market dynamics shift.
Vishnu Lekraj
Premium Article

4 Doorbusters for Investors

These high-quality stocks are cheap on a host of metrics.
Susan Dziubinski
Investing Specialists

More Tax Pain for Some Mutual Fund Shareholders in 2018

Ongoing redemptions from active funds and a long-running bull market mean tax pain for many fund investors in taxable accounts.
Christine Benz
Investing Specialists

Tax-Loss Selling: A Silver Lining in Volatile Markets

Pruning losers can reduce the tax hit from rebalancing and mutual fund capital gains distributions.
Christine Benz
Stock Strategist

McKesson Is Deeply Discounted

The pharma distributor has a solid foundation and a bright outlook, in our opinion.
Vishnu Lekraj